Showing: 1 - 9 of 9 RESULTS

Twentyeight Health is a telemedicine company expanding access to women’s health and reproductive care

New York’s Twentyeight Health is taking the wildly telemedicine services for women’s health popularized by companies like Nurx and bringing them to a patient population that previously hadn’t had access. 

The mission to provide women who are Medicaid or underinsured should not be deprived of the same kinds of care that patients who have more income security or better healthcare coverage enjoy, according to the company’s founder, Amy Fan.

The mission, and the company’s technology, have managed to convince a slew of investors who have poured $5.1 million in seed funding into the new startup. Third Prime led the round, which included investments from Town Hall Ventures, SteelSky Ventures, Aglaé Ventures, GingerBread Capital, Rucker Park Capital, Predictive VC, and angel investors like Stu Libby, Zoe Barry, and Wan Li Zhu.

“Women who are on Medicaid, who are underinsured or without health insurance often struggle to find access to reproductive health services, and these struggles have only increased with COVID-19 pandemic limiting access to in-person appointments,” said Amy Fan, co-founder of Twentyeight Health, in a statement. “We are fighting for healthcare equity, ensuring that all women, particularly BIPOC women and women from low-income backgrounds, can access high quality, dignified and convenient care.”

To ensure that its catering to underserved communities, the company works with Bottomless Closet, a workforce entry program for women, and the 8 colleges in the City University of New York ecosystem including LaGuardia College, which has 45,000 students with 70% coming from families making less than $30,000 in annual income.

The company’s services are currently available across Florida, Maryland, New York, New Jersey, North Carolina and Pennsylvania and it’s the only telemedicine company focused on contraception services to accept Medicaid.

In another example of how awesome this company is, it’s also working to provide free birth control for women who aren’t able to pay out of pocket and are uninsured through a partnership with Bedsider’s Contraceptive Access Fund. The company also donates 2% of its revenue to Bedsider and the National Institute for Reproductive Health. (Y’all, this company is amaze.)

To sign up for the service, new customers fill out a medical questionnaire online. Once the questionnaire is reviewed by a US board-certified doctor within 24 hours customers can access over 100 FDA-approved brands of birth control pills, patches, rings, shots, and emergency contraception and receive a shipment within three days.

Twentyeight Health provides ongoing care through online audio consultations and doctor follow up messages to discuss issues around updating prescriptions or addressing side effects, the company said.

“Today, low-income women are three times more likely to have an unintended pregnancy than the average woman in the U.S., and nearly one-third of physicians nationwide aren’t accepting new Medicaid patients,” said Bruno Van Tuykom, co-founder of Twentyeight Health, in a statement. “This underscores why offering high-quality reproductive care that is inclusive of people across race, income bracket, or health insurance status is more important than ever.”

Launched in 2018, Twentyeight Health said it would use the new

Fitness tech company JAXJOX raises $10M as it gets ready to ship AI-enabled workout system



The JAXJOX InteractiveStudio exercise system. (JAXJOX Photo)


© Provided by Geekwire
The JAXJOX InteractiveStudio exercise system. (JAXJOX Photo)

JAXJOX, the Redmond, Wash.-based fitness technology company, has raised $10 million in a new funding round to help pay for the research and development of its signature InteractiveStudio workout equipment.

Loading...

Load Error

The Series A round included investors Dowgate Capital Ltd. and entrepreneur Nigel Wray, and brings total funding to $17 million for the 3-year-old company.

JAXJOX is getting set to release its InteractiveStudio smart gym, a home fitness system that includes digitally adjustable weights, AI-enabled connected tech built into the equipment, and live and on-demand classes.

With connected tech built into individual pieces of free-weight equipment, such as a smart kettlebell, users don’t have to stand a certain distance from a screen to have form and motion tracked.

“By monitoring performance metrics and using AI, we can give users a more holistic view of their health and provide recommendations on improving their wellbeing,” founder and CEO Stephen Owusu said in a news release. “We believe that, for users, tracking power generated while lifting will become as important as tracking your heart rate while running.”

The InteractiveStudio is available for pre-order on the JAXJOX website and retails for $2,199 with a $39 monthly subscription. The system will also sell as part of an exclusive retail partnership this fall with Best Buy.

Continue Reading

Source Article

Jennifer Kocour Named Chief Operating Officer of CCT Research as Company Continues U.S. Expansion

An experienced clinical research leader, Kocour will oversee business operations and strategic growth for the CCT Network of Sites

CCT Research, a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases, announced today that Jennifer Kocour has joined the company as its Chief Operating Officer. Kocour brings a wealth of industry experience, having started her career as a Clinical Research Assistant before advancing to roles as a Site Coordinator, Regional Manager, Clinical Team Lead, and Vice President of Operations.

Kocour’s appointment comes as CCT Research continues to rapidly expand its geographic and therapeutic reach since opening its doors in 2017. “I’m excited to join a company that’s dedicated to industry innovation, exceptional patient care, and the growth and development of our staff as we continue to grow as a company,” said Kocour.

CCT Research currently has 17 sites across Arizona, Nebraska, and Utah. The sites are located in physicians’ offices, medical clinics, and senior living communities; and the company is looking to add partner sites in new markets. By embedding its clinical research infrastructure and staff into these facilities, CCT Research provides convenient and comfortable study locations for qualified patients in a variety of therapeutic areas. Recently, the company was selected to partner with several top pharmaceutical companies to conduct trials for a COVID-19 vaccine.

“Strong leadership is key to supporting these critical study efforts and future medical research,” said CJ Anderson, President of CCT Research. “Jennifer is a proven leader, and her diverse background provides an understanding of each individual’s role in conducting a successful clinical trial. We’re happy to have her as the newest member of our executive leadership team.”

About CCT Research

CCT Research is a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases. CCT’s research sites are located within physicians’ offices, medical clinics, and senior living communities to support research in the fields of Neurology, Family Practice, and Dermatology, with plans to include additional therapy areas in the near future. The company’s unique model simplifies the process for trial participants and provides pharmaceutical sponsors with high quality data. For more information, visit cctresearch.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005945/en/

Contacts

CJ Anderson, President
CCT Research
480-702-3501
[email protected]

Source Article

JAXJOX, the Leading Fitness Technology Company, Raises $10M in Series A Funding

SEATTLE, Oct. 13, 2020 /PRNewswire/ — JAXJOX, the global fitness technology company known for its innovative workout equipment and platform, today announced a $10M series A round of funding with investors including Dowgate Capital Ltd. and entrepreneur Nigel Wray, bringing total funding raised to date $17M. The funding assisted in the research and development of the highly anticipated JAXJOX InteractiveStudio, which will ship to customers later this year, as well as global retail expansion. The InteractiveStudio is the first fitness platform to combine connected strength-training equipment with live and on-demand content, enabling users to track their own performance in real time during classes.

“With so much activity in the connected fitness space, we’re both delighted and excited to be part of JAXJOX’s movement to bring fitness and health together using data science. This is the future of wellness,” said James Sergeant of Dowgate Capital.

The InteractiveStudio is the first home gym that includes connected free-weight equipment with AI-enabled performance tracking and interactive live and on-demand coaching for a personalized workout experience. Four connected, IP-protected products with automatic adjustability use AI powered real-time performance tracking, including the groundbreaking KettlebellConnect 2.0 and DumbbellConnect. Compared to other products in the space, the InteractiveStudio provides a substantially richer training experience with personalized, real-time data including repetitions, total volume, power and a proprietary Fitness IQ score.

“When developing the InteractiveStudio it was important for us to think about all the friction points a user experiences with home gym equipment. A few years ago, there were no in-home fitness solutions that fit into every lifestyle. There were in-home solutions for cardio and strength but nothing that combined the two in one compact unit. We spent 2 years creating the ultimate community-centric home fitness solution that combines adjustable free-weight equipment, AI-powered performance tracking, and content for a wide variety of workouts,” said Founder and CEO Stephen Owusu.

Unlike other home fitness systems that require users to stand a certain distance from their screen to track form and motion, JAXJOX’s connected technology is built into the products, providing the most versatile experience for training. Users can remove any connected product from the studio and workout in a different location, while still accessing the live coaching and performance tracking on their mobile app.

JAXJOX uses a proprietary machine learning algorithm to calculate the user’s Fitness IQ score. The score keeps them informed on overall progress toward fitness goals and can also provide personal workout recommendations. JAXJOX uses peak and average power, heart rate, workout consistency, steps, body weight, and your chosen fitness level in the calculation.

“Beyond fitness-tech products, our vision is to close the gap between fitness and health. By monitoring performance metrics and using AI, we can give users a more holistic view of their health and provide recommendations on improving their wellbeing. We know working out is only one aspect of wellness and

UAE company nears end of Chinese Covid-19 vaccine trial

ABU DHABI (Reuters) – A United Arab Emirates company is nearing the end of Phase III clinical trials of a Chinese COVID-19 vaccine and hopes to manufacture it next year, a representative said.

The trial, which began in mid-July, is a partnership between Sinopharm’s China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42).

The vaccine uses an inactivated virus; a well-known technology which has been used against diseases such as influenza and measles. Two doses are given.

It has been administered to more than 31,000 people in the UAE, Egypt, Bahrain and Jordan, G42 Healthcare CEO Ashish Koshy said.

Results analysis and publication will happen in around two months, Koshy said.

He said G42 has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other regional states with the vaccine, especially those that participated in the trial.

The target is to produce between 75 and 100 million doses next year in the UAE, he said.

“Early results are showing it is safe, there is a general rise in antibodies for all the volunteers,” Koshy said. “In terms of being effective it is on the journey, but only time will tell in terms of the whole picture.”

Emirati volunteer Wo’oud al-Motawaa was vaccinated around two months ago and returned to the facility in the emirate of Abu Dhabi for one of her follow-up checks.

“I work in a hospital so it was something that we want to help with,” she said. “We trust our country.”

G42 has said the UAE population’s diversity was an asset, offering around 200 different nationalities. Koshy said around 125 nationalities had participated so far.

The UAE, whose tally stands at more than 101,000 infections and 435 deaths, has seen the number of daily new coronavirus cases surge over the past two months from 164 on Aug. 3 to a high of 1,231 cases last week.

The UAE has a high per capita rate of COVID-19 tests, having carried out more than 10 million tests in a population of around 9.9 million, the government statistics authority says.

(Reporting by Jacob Greaves; Writing by Lisa Barrington; Editing by Alexandra Hudson)

Source Article

Trump has personally pressured drug company CEOs repeatedly to speed vaccine

A likely contagious President Donald Trump returned to the White House Monday evening, whipped off his mask and filmed a video, heavy on bluster and short on facts, that proclaimed: “The vaccines are coming momentarily.”



Donald Trump wearing a suit and tie: WASHINGTON, DC - SEPTEMBER 30: U.S. President Donald Trump speaks to reporters on his way to Marine One on the South Lawn of the White House on September 30, 2020 in Washington, DC. President Trump is traveling to Minnesota for a fundraising event and a campaign rally. (Photo by Drew Angerer/Getty Images)


© Drew Angerer/Getty Images
WASHINGTON, DC – SEPTEMBER 30: U.S. President Donald Trump speaks to reporters on his way to Marine One on the South Lawn of the White House on September 30, 2020 in Washington, DC. President Trump is traveling to Minnesota for a fundraising event and a campaign rally. (Photo by Drew Angerer/Getty Images)

Trump, who tested positive for coronavirus last week and is now receiving medical care at the White House, has remained laser-focused on vaccine development even as he has been dismissive of mask-wearing and social distancing — protections health experts say are critical to stopping the spread of the coronavirus.

Even before his diagnosis, the President had taken to calling drug companies to check on their vaccine trials, asking how much longer they’ll take and ginning up the pressure around his desire for a vaccine before Election Day.

In his conversations with major drug-makers working on coronavirus vaccines, Trump has been explicit in telling the companies’ CEOs that he’d like to see a vaccine move quicker than some of his health advisers say is reasonable, according to a person familiar with the conversations. He has asked whether they believe they can speed up their timelines and has suggested he is concerned that the FDA’s regulatory process could slow down progress.

In a tweet Tuesday night, Trump slammed new rules from the agency that would make it nearly impossible for a vaccine to be approved ahead of the election, calling them a “political hit job.”

“New FDA Rules make it more difficult for them to speed up vaccines for approval before Election Day. Just another political hit job!” he wrote in the tweet, which he aimed at FDA commissioner Dr. Stephen Hahn.

Trump’s repeated calls — especially to Pfizer, whose progress the President sounds most hopeful about recently — are likely to continue through a presidential election that may turn on how voters perceive his handling of the public health crisis.

Meantime, experts worry what Trump’s undivided attention means for the fate of the vaccine. With so much obvious political pressure coming to bear, people may fear that the vaccines aren’t safe for widespread use. Beyond that, they may lose trust in federal regulators and, possibly, in research science.

The political climate surrounding a potential coronavirus vaccine already has scientists cringing.

“There just seems to be this huge pressure from an administration that has been very effective at getting everything wrong,” said Dr. Esther Choo, an emergency medicine physician and professor at Oregon Health & Science University. “So, it’s like, how can this go well?”

White House spokeswoman Sarah Matthews dismissed those concerns.

“This President understands that this vaccine cannot get bogged down in government bureaucracy,” Matthews said. “The Trump administration is focused on delivering a safe, effective vaccine to

Bristol Myers Squibb buys biopharma company MyoKardia for $13B

Oct. 5 (UPI) — Bristol Myers Squibb said Monday it will buy biopharmaceutical company MyoKardia for $13 billion, its second large acquisition in two years.

MyoKardia, which develops therapies for serious cardiovascular diseases, produces mavacamten, a potential medicine to treat the chronic heart disease obstructive hypertrophic cardiomyopathy.

“We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease,” Bristol Myers Squibb CEO Dr. Giovanni Caforio said in a statement.

MykoKardia CEO Tassos Gianakakos said the company was created eight years ago to address serious cardiovascular disease with “bold and innovative science.” Since then, he said, it’s produced treatments to help heart function after illness.

“Bristol Myers Squibb shares our vision for transforming the treatment of cardiovascular disease,” Gianakokos said in a statement. “They value our team and the potential of our platform and, most importantly, share our unwavering commitment to placing patients at the center of everything we do.”

Bristol Myers Squibb last year bought cancer drug company Celgene for $74 billion. Celgene produces oncology drugs such as Opdivo, Yervoy, Revlimid and Pomalyst.

Sign up for our daily Top News Newsletter

Source Article

Donald Trump’s positive coronavirus test puts him in the company of Boris Johnson and Jair Bolsonaro



Boris Johnson wearing a suit and tie: HERTFORD, ENGLAND - DECEMBER 04: British Prime Minister Boris Johnson shakes hands with US President Donald Trump onstage during the annual NATO heads of government summit on December 4, 2019 in Watford, England. France and the UK signed the Treaty of Dunkirk in 1947 in the aftermath of WW2 cementing a mutual alliance in the event of an attack by Germany or the Soviet Union. The Benelux countries joined the Treaty and in April 1949 expanded further to include North America and Canada followed by Portugal, Italy, Norway, Denmark and Iceland. This new military alliance became the North Atlantic Treaty Organisation (NATO). The organisation grew with Greece and Turkey becoming members and a re-armed West Germany was permitted in 1955. This encouraged the creation of the Soviet-led Warsaw Pact delineating the two sides of the Cold War. This year marks the 70th anniversary of NATO. (Photo by Steve Parsons-WPA Pool/Getty Images)


© Steve Parsons/Pool via Getty
HERTFORD, ENGLAND – DECEMBER 04: British Prime Minister Boris Johnson shakes hands with US President Donald Trump onstage during the annual NATO heads of government summit on December 4, 2019 in Watford, England. France and the UK signed the Treaty of Dunkirk in 1947 in the aftermath of WW2 cementing a mutual alliance in the event of an attack by Germany or the Soviet Union. The Benelux countries joined the Treaty and in April 1949 expanded further to include North America and Canada followed by Portugal, Italy, Norway, Denmark and Iceland. This new military alliance became the North Atlantic Treaty Organisation (NATO). The organisation grew with Greece and Turkey becoming members and a re-armed West Germany was permitted in 1955. This encouraged the creation of the Soviet-led Warsaw Pact delineating the two sides of the Cold War. This year marks the 70th anniversary of NATO. (Photo by Steve Parsons-WPA Pool/Getty Images)

US President Donald Trump is not the only leader on the world stage to have contracted coronavirus.

His positive test, announced in the early hours of Friday, puts him in the company of UK Prime Minister Boris Johnson, Brazil’s Jair Bolsonaro and Russian Prime Minister Mikhail Mishustin.

Of those, Johnson fell the most gravely ill after he tested positive for the virus at the end of March. He spent a week in hospital, with three nights in intensive care and, on being discharged admitted “things could have gone either way” for him. Even after leaving the hospital, he had to spend time recuperating at his official country residence, Chequers.

Johnson’s illness, at the height of Britain’s first wave of infections, complicated the government’s response, not least because the virus spread through the government’s ranks in Westminster.

Trump and his wife Melania, who has also tested positive for the virus, may be asymptomatic or have only mild symptoms, as was the case with Britain’s health minister Matt Hancock.

At 74 years old and overweight, Trump — who has spent months playing down the severity of the pandemic as US deaths have surpassed 207,000 — falls into the highest risk category for serious complications from the disease. But the first lady, age 50, is likely to be at a lower risk of serious illness.

Johnson tweeted his best wishes to Trump and the first lady, saying he hoped “they both have a speedy recovery from coronavirus.”

The US President and first lady can expect to receive the best care the country can offer. But some fear that the full picture is not being given.

Even when the British Prime Minister was in hospital, daily briefings from Downing Street breezily proclaimed he was in “good spirits” when in fact — by Johnson’s own account later — the situation was significantly more serious.

Disregard for masks, distancing

In Brazil, populist leader Bolsonaro, like Trump, spent months downplaying the threat from coronavirus, like Trump, dismissing it as just a “little flu” and assuring his compatriots they had little

Regenerative medicine company Aziyo Biologics sets terms for $50 million IPO

Aziyo Biologics, which makes regenerative medical products for various tissue types, announced terms for its IPO on Wednesday.

The Silver Spring, MD-based company plans to raise $50 million by offering 2.9 million shares at a price range of $16 to $18. Insiders intend to purchase $20 million worth of shares in the offering. At the midpoint of the proposed range, Aziyo Biologics would command a fully diluted market value of $177 million.

Through its proprietary tissue processing platforms, the company has developed a portfolio of advanced regenerative medical products designed to be similar to natural biological material. Its core products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. 

Aziyo Biologics was founded in 2015 and booked $42 million in revenue for the 12 months ended June 30, 2020. It plans to list on the Nasdaq under the symbol AZYO. Piper Sandler, Cowen, Cantor Fitzgerald and Truist Securities are the joint bookrunners on the deal. It is expected to price on Wednesday, October 7, 2020.

The article Regenerative medicine company Aziyo Biologics sets terms for $50 million IPO originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article